Digestive and breast cancer patients managed during the first wave of COVID-19 pandemic: Short and middle term outcomes

Table 9 Characteristics of gastric and oesophageal cancer and performed surgeries

Gastric and oesophageal cancer [n (%)]		Gastric, n = 7 (5 operated)	Oesophageal, n = 2
Final TNM staging	IB	1 (14.3)1
	I-E	1 (14.3)2
	IIA	2 (28.6), 13
	IIIA	1 (14.3)3
	IIIB		2 (100)
	IIIC	2 (28.6)
Location	Middle third		1 (50.0)
	Lower third – GEJ		1 (50.0)
	Proximal	2 (40.0)
	Distal	3 (60.0)
Histology	Adenocarcinoma	3 (60.0)	1 (50.0)
	Squamous cell		1 (50.0)
	Other	1 GIST (20.0) 1 lymphoma (20.0)
Neoadjuvant therapy	Long-course RT+CT		2
	Long-course CT	2 (40%)
Previous COVID		1 (20.0%)	0
CRITCON level	0	3 (60.0)	1 (50.0)
	1	1 (20.0)	1 (50.0)
	2	1 (20.0)
Urgency	Urgent/Expedited
	Elective
Operative approach	Open	1 (20.0)	2 (100.0)
	MIS	3 (60.0)	0
	MIS-open	1 (20.0)	0
Resection	R0	5 (100)	1 (50.0)
	R1	0	1 (50.0)
	R2	0	0

¹GIST patient.

²Lymphoma patient.

³1 non-operated patient.

GEJ: Gastro-oesophageal junction; RT: Radiotherapy; CT: Chemotherapy; MIS: Minimally invasive surgery; R0: No microscopic disease; R1: Microscopic disease; R2: Macroscopic disease at margin.